Treatment with Enspryng (satralizumab) was associated with fewer attacks and improved disability scores among people with neuromyelitis optica spectrum disorder (NMOSD) in a real-world study in China. The findings included patients who switched from other treatments. “Collectively, these findings extend current real-world evidence on [Enspryng] across clinically…
Discussion
For National Family Caregivers Month, I asked my husband of 16 years (20 years together) to be a guest columnist. My only request, aside from the word count, was that Mike write about being my husband first, and sometimes my caregiver, and what that intersection looks like for him. Mike…
Discussion
CRISPR Therapeutics has launched a Phase 1 clinical trial to test its experimental cell therapy zugocabtagene geleucel (zugo-cel) in adults with relapsing neuromyelitis optica spectrum disorder (NMOSD), which means the disease is flaring. The Phase 1 study (NCT07804004) is also open to adults with other autoimmune conditions…
NMOSD is a progressive autoimmune disease where the immune system mistakenly attacks nerve cells, affecting the nervous system. Learn more about the disease here.
Scientists do not know the exact underlying cause of NMOSD. Self-reactive antibodies that target AQP4 are known to play a major role. Learn more about what causes the disease here.
When the disease affects the optic nerve (optic neuritis), it can result in pain inside the eye and possibly blurry vision or vision loss. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
